CENTOGENE Extends Partnership With Takeda

Advertisement - Oliver

Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has extended its partnership with Takeda Pharmaceutical Company Limited  to diagnose patients with certain genetic disorders.

As part of the agreement, which has been extended until March 2022, CENTOGENE will continue providing access to genetic testing to patients around the world.

Andrin Oswald, M.D., CEO of CENTOGENE, said, “We are pleased to be extending our partnership with Takeda, which will allow us to continue diagnosing and connecting rare disease patients globally. There is still a lot of work to be done, but with each step, we are closer to bringing patients the life-saving medical solutions they need.”

In January 2015, CENTOGENE originally entered into an agreement with Shire Pharmaceuticals, which is now a subsidiary of Takeda Pharmaceutical Company Limited, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from genetic rare diseases.